Survival in MDS Equivalent With Reduced-Intensity Conditioning

Patients with myelodysplastic syndrome undergoing a reduced –intensity conditioning regimen prior to allogeneic stem-cell transplantation had similar 2-year survival outcomes as patients who underwent myeloablative conditioning.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Tags: Hematologic Malignancies Myelodysplastic Syndromes News Source Type: news

Related Links:

ConclusionWe confirmed that myeloablative Bu/Flu conditioning has comparable clinical and QOL outcomes to Bu/Cy.
Source: Hematology Oncology and Stem Cell Therapy - Category: Cancer & Oncology Source Type: research
Publication date: Available online 9 October 2019Source: The Lancet HaematologyAuthor(s): Dietrich Wilhelm Beelen, Rudolf Trenschel, Matthias Stelljes, Christoph Groth, Tamás Masszi, Péter Reményi, Eva-Maria Wagner-Drouet, Beate Hauptrock, Peter Dreger, Thomas Luft, Wolfgang Bethge, Wichard Vogel, Fabio Ciceri, Jacopo Peccatori, Friedrich Stölzel, Johannes Schetelig, Christian Junghanß, Christina Grosse-Thie, Mauricette Michallet, Hélène Labussiere-WalletSummaryBackgroundFurther improvement of preparative regimens before allogeneic haemopoietic stem cell transplantation (HSCT) ...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Natural killer (NK) cells are large granular lymphocytes involved in our defense against certain virus-infected and malignant cells. In contrast to T cells, NK cells elicit rapid anti-tumor responses based on signals from activating and inhibitory cell surface receptors. They also lyse target cells via antibody-dependent cellular cytotoxicity, a critical mode of action of several therapeutic antibodies used to treat cancer. A body of evidence shows that NK cells can exhibit potent anti-tumor activity against chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS). However, disease-...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
ix H, Duarte RF, Basak GW Abstract Uric acid is a danger signal contributing to inflammation. Its relevance to allogeneic stem cell transplantation derives from preclinical models where the depletion of uric acid led to improved survival and reduced graft-versus-host disease. In a clinical pilot trial, peri-transplant uric acid depletion reduced acute graft-versus-host disease incidence. This prospective international multicenter study aimed to investigate the association of uric acid serum levels before start of conditioning with allogeneic stem cell transplantation outcome. We included patients with acute leukem...
Source: Haematologica - Category: Hematology Authors: Tags: Haematologica Source Type: research
Serum ferritin (SF) has been identified as a potential prognostic factor for patients undergoing stem cell transplantation, but the prognostic value of SF in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients and the impact of iron chelation therapy (ICT) on MDS patients are controversial. The present meta-analysis aimed to better elucidate these relationships. Three electronic databases were searched systematically to identify reports on the prognostic role of SF in MDS and AML patients, and those investigating the impact of ICT on prognosis of MDS patients. The hazard ratios (HRs) and its 95% conf...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Meta-Analysis of Observational Studies in Epidemiology Source Type: research
ConclusionsDLI was associated with a durable efficacy and low toxicity in pediatric patients with hematologic malignancies. However, larger studies and standardized approaches are required to identify the outcome predictors of this treatment modality.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Hematopoietic stem cell transplantation from alternative donors is becoming an increasingly important option. Since HLA-mismatched umbilical cord blood transplantation (CBT) was introduced as a treatment option for adult hematological disease around 2000 [1,2], transplant outcomes with CBT have gradually improved [3]. However, because CB was assessed as an alternative donor source, second to unrelated volunteer donor in the earlier era, the patient's physical condition sometimes deteriorated with a prolonged donor search and the patient missed optimal transplant timing.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Owing to poor prognosis and limited therapeutic modalities, treatment of myelodysplastic syndromes (MDS) and myelodysplastic/myeloproliferative neoplasms (MDS/MPN) has long been a challenge for researchers [1,2]. In recent years, allogeneic hematopoietic stem cell transplantation (allo-HSCT) has provided a potential curative therapy for patients with MDS and MDS/MPN. However, relapse, treatment-related death, and non-relapse mortality (NRM) – which are often related to graft-versus-host disease (GVHD)—remain major obstacles to universally successful transplantation.
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
Publication date: Available online 7 August 2019Source: The Lancet HaematologyAuthor(s): Farhad Ravandi, Rita Assi, Naval Daver, Christopher B Benton, Tapan Kadia, Philip A Thompson, Gautam Borthakur, Yesid Alvarado, Elias J Jabbour, Marina Konopleva, Koichi Takahashi, Steven Kornblau, Courtney D DiNardo, Zeev Estrov, Wilmer Flores, Sreyashi Basu, James Allison, Padmanee Sharma, Sherry Pierce, Allison PikeSummaryBackgroundOutcomes for younger patients with acute myeloid leukaemia have moderately improved over the past two decades owing to better supportive care and recent introduction of novel targeted agents. Blocking PD-...
Source: The Lancet Haematology - Category: Hematology Source Type: research
Authors: Germing U, Schroeder T, Kaivers J, Kündgen A, Kobbe G, Gattermann N Abstract Introduction: Myelodysplastic syndromes (MDS) comprise a heterogeneous group of myeloid neoplasms with diverse clinical courses. The revised version of the international prognostic scoring system (IPSS-R) provides risk stratification into 5 different groups. Areas covered: For lower-risk patients, red blood cell transfusions and iron chelation are the backbone of supportive care. In addition, erythropoiesis-stimulating agents (ESA) are used to ameliorate anemia. Lenalidomide is approved for the treatment of lower-risk patient...
Source: Expert Review of Hematology - Category: Hematology Tags: Expert Rev Hematol Source Type: research
More News: Cancer & Oncology | Hematology | Legislation | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Transplants